ClinicalTrials.gg
Not yet recruitingNCT07941037Updated Nov 17, 2026

Effect of Non-Compressive Semiconductor Embedded Therapeutic Gloves on Osteoarthritis of the Hand

An interventional study of Incrediwear Semiconductor-Embedded Gloves and Placebo Gloves in Hand Osteoarthritis, sponsored by MSK Doctors & Associates Ltd. Not yet recruiting. Open to participants aged 39 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by MSK Doctors & Associates Ltd · Not applicable, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
39 Years and older
Sex
All
01

Study summary

This clinical trial will investigate whether non-compressive therapeutic gloves improve hand function and reduce pain in people with hand osteoarthritis. The gloves contain semiconductor elements embedded in their fabric. Researchers will compare these gloves with visually identical placebo gloves that do not contain semiconductor elements.

The main question is whether the active gloves improve hand function after 12 weeks compared with placebo gloves. Researchers will also assess pain, grip strength, symptoms and changes seen on magnetic resonance imaging (MRI) over nine months.

The study will involve at least 154 participants aged 39 years or older with diagnosed hand osteoarthritis who do not require immediate hand surgery. It will take place at MSK House in Sleaford, United Kingdom.

After providing written informed consent, participants will be assigned by chance to one of two groups. Each participant will have an equal chance of receiving active or placebo gloves. Neither participants nor the clinical team will know which gloves have been assigned.

Participants will:

  • Wear the assigned glove or gloves on their affected hand or hands for at least 20 hours each day, including overnight, during the first 12 weeks.
  • Continue wearing the gloves for at least 12 hours each day, including overnight, for the remainder of the nine-month study.
  • Complete questionnaires about hand pain and function before treatment and at three, six and nine months.
  • Attend the study site at the beginning and at nine months for assessments, including grip strength testing and MRI scans of the hand and wrist.
  • Record their hand pain, glove use and pain medication use in a weekly diary.

Participants may also complete a short video-based movement assessment at the first and last study visits.

The main measure of hand function will be the Australian Canadian Osteoarthritis Hand Index (AUSCAN), a questionnaire about hand symptoms and difficulty with everyday activities. Other assessments will measure pain, hand function, grip strength and changes in the hand joints.

The research team will record unwanted effects during the study. Participants who experience discomfort, irritation or a skin reaction will be advised to remove the gloves and contact the study team.

The findings will help determine whether these therapeutic gloves have a role in managing hand osteoarthritis.

02

Conditions studied

  • Hand Osteoarthritis

Browse trials for

Keywords

  • Therapeutic gloves
  • Non-compressive gloves
  • Semiconductor embedded fabric
  • Hand pain
  • Hand function
  • Grip strength
  • Incrediwear
03

In context

Osteoarthritis

2,977 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

This study's planned enrollment of 154 is above the median of 80 across 2,241 interventional studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

MSK Doctors & Associates Ltd is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
39 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed erosive hand osteoarthritis, non-erosive hand osteoarthritis or first carpometacarpal joint osteoarthritis.
  • Mild, moderate or severe hand osteoarthritis on MRI assessment, without an indication for immediate surgery.
  • Hand pain attributable to diagnosed hand osteoarthritis within the previous six months.
  • Aged 39 years or older.
  • Willing and able to comply with the follow-up schedule and study requirements.
  • Willing and able to provide written .

Exclusion criteria

Exclusion Criteria:

  • Known history of neurological conditions, including multiple sclerosis or Parkinson's disease.
  • Surgical treatment of the hands within the previous five years or injection treatment of the hands within the previous six months.
  • An indication for immediate surgery to treat hand osteoarthritis.
  • Secondary causes of arthritis, including gout, rheumatoid arthritis or psoriatic arthritis.
  • Use of topical creams or gels for arthritic pain within the previous week, including non-steroidal anti-inflammatory drugs, capsaicin, lidocaine or counterirritants.
  • History of carpal tunnel syndrome, cubital tunnel syndrome or radial tunnel syndrome.
  • History of peripheral neuropathy.
  • Chronic pain conditions unrelated to the hand condition.
  • Known disease other than arthritis.
  • Tobacco use within the previous 90 days.
  • Aged under 39 years.
  • Active local or systemic infection.
  • Unwilling or unable to provide written .
  • Any other condition or circumstance that, in the investigator's opinion, would prevent completion of the study or confound the study results.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
154 participants (estimated)

Study arms

  • Experimental
    Icrediwear Group

    Participants receive active semiconductor-embedded gloves to wear on their affected hand or hands for nine months. Gloves are worn for a minimum of 20 hours per day, including overnight, during the first 12 weeks, followed by at least 12 hours per day, including overnight, until the nine-month assessment.

    Device: Incrediwear Semiconductor-Embedded Gloves

  • Placebo comparator
    Placebo Group

    Participants receive identical gloves without semiconductor elements to wear on their affected hand or hands for nine months. Gloves are worn for a minimum of 20 hours per day, including overnight, during the first 12 weeks, followed by at least 12 hours per day, including overnight, until the nine-month assessment.

    Other: Placebo Gloves

Interventions

  • DeviceIncrediwear Semiconductor-Embedded Gloves

    Non-compressive therapeutic gloves with semiconductor elements incorporated into the fabric. The gloves cover the hand and fingers, with open fingertips. The research team selects the appropriate size, fits the gloves and provides instructions for use.

  • OtherPlacebo Gloves

    Visually identical non-compressive gloves without semiconductor elements. The gloves cover the hand and fingers, with open fingertips. The research team selects the appropriate size, fits the gloves and provides instructions for use.

06

What researchers measure

Primary outcomes

  1. Change in Hand Function Assessed Using the Australian Canadian Osteoarthritis Hand Index (AUSCAN)

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Change in Hand Pain Assessed Using a Visual Analogue Scale

    Time frame: Baseline and months 3, 6 and 9.

  2. Change in Functional Index for Hand Osteoarthritis (FIHOA) Score

    Time frame: Baseline and months 3, 6 and 9.

  3. Change in Grip Strength

    Time frame: Baseline and month 9.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Mar 2027, 3 months later.

Of 135 industry-sponsored interventional studies with no phase under Osteoarthritis, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 81. This study's planned 3 months is below that.

Counting every sponsor, half of 711 studies reached it within 28 months; a quarter within 11 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Dec 2026
Primary completionEst.
Mar 2027
CompletionEst.
Oct 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941037
Lead sponsor
MSK Doctors & Associates Ltd
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Dec 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Paul Lee
Contact
research@mskdoctors.com
+44 330 001 0048

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion